Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms

BACKGROUND: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders (KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukem...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kampa-Schittenhelm, Kerstin Maria, Heinrich, Michael Charles, Akmut, Figen, Döhner, Hartmut, Döhner, Konstanze, Schittenhelm, Marcus Matthias
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3637582/
https://ncbi.nlm.nih.gov/pubmed/23497317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-12-19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares